Is Canada losing its status as a priority medicine launch country? - Insights from IQVIA
Canada has long been considered a priority country for new medicine launches. However, ongoing and unpredictable changes to the pharmaceutical policy environment have caused market uncertainty, which has impacted Canada’s ability to maintain this status. To help inform and contribute to this discussion, Life Sciences Ontario commissioned IQVIA – a global leader in health data and analytics – to update research from 2020 to determine whether Canada has seen further changes to its global standing.